NewAmsterdam Pharma Company N.V.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| NAMS | B9A.F | GPCR | MAZE | PHAR | LXRX | |
|---|---|---|---|---|---|---|
| Market cap | 2.45B | 2.45B | 1.45B | 1.85B | 881.90M | 658.53M |
| P/E (TTM) | — | 250.7 | — | — | 38.9 | — |
| Forward P/E | -13.7 | — | -9.6 | -10.5 | 69.2 | -7.8 |
| Price/book | 3.5 | 1.2 | 1.1 | 4.1 | 2.9 | 3.8 |
| Dividend yield | — | 0.68% | — | — | — | — |
| 1-year change | −47.80% | +5.23% | −36.82% | +6.54% | −1.90% | +5.80% |
| Today | +5.18% | −0.29% | +0.05% | +3.50% | −3.63% | +1.37% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All NAMS news ›NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in November
The Manila Times NAARDEN, The Netherlands and MIAMI, Nov. 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam” or the "Company”), a late-stage, clinical biopharmaceutical company
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Stock Has Consensus Price Target of $48.90 According to Analysts
Posted by Tristan Rich on Nov 1st, 2026 Check Out Our Latest Stock Report on NAMS Shares of NAMS opened at $20.06 on Friday. NewAmsterdam Pharma has a 1 year low of $19.13 and a 1 year high of $42.21. The company has a market cap of $2.40…
Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM
The findings from BROADWAY and TANDEM, presented yesterday at the 2025 European Atherosclerosis Society Congress and simultaneously published in the New England Journal of Medicine and the Lancet, respectively, represent great possibility:…
NewAmsterdam Pharma (NASDAQ:NAMS) Cut to “Sell” at Wall Street Zen
Posted by Tristan Rich on Oct 27th, 2026 Wall Street Zen cut shares of NewAmsterdam Pharma (NASDAQ:NAMS – Free Report) from a hold rating to a sell rating in a research report sent to investors on Saturday,Wall Street Zen reports. Read Our…
Analysts Are Bullish on Top Healthcare Stocks: Invivyd (IVVD), NewAmsterdam Pharma Company (NAMS)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Invivyd (IVVD), NewAmsterdam Pharma Company (NAMS) and Kura Oncology (KURA) with bullish sentiments. In a report released today, Patrick…
NewAmsterdam Pharma (NASDAQ:NAMS) vs. ADC Therapeutics (NYSE:ADCT) Financial Analysis
NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) and ADC Therapeutics (NYSE:ADCT – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their…
NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial
-- Pre-specified analyses show that obicetrapib treatment leads to statistically significant and clinically meaningful reductions in the primary outcome measure of Alzheimer’s disease biomarker in both the full ITT population (p --…
NewAmsterdam Pharma (NASDAQ:NAMS) Hits New 12-Month Low – What’s Next?
Posted by Kim Johansen on Oct 8th, 2026 NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Get Free Report)’s share price reached a new 52-week low during mid-day trading on Thursday. The stock traded as low as $20.95 and last traded at…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- themarketsdaily.com3
- defenseworld.net1
- manilatimes.net1
- markets.businessinsider.com1
- tradingview.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 7 articles, not a forecast.